{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "Hsiao_et_al.__2023_"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "METHODS In this cluster randomized observational study, Kaiser Permanente Northern Cali- for nia facilities routinely administered either a high dose recombinant influenza vaccine (Flublok Quad rival ent or one of two standard dose influenza vaccines during the 2018-2019 and 2019-2020 influenza seasons to adults 50 to 64 years of age (primary age group) and 18 to 49 years of age. Each facility alternated weekly between the two vaccine formulations.",
      "relevance_explanation": "This quote directly states that Flublok Quadrivalent (the high dose recombinant vaccine) was evaluated against standard dose influenza vaccines in a comparative study, supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "To estimate the relative effectiveness of the recombinant vaccine as compared with standard- dose vaccines against laboratory confirmed in- flue nza and influenza related outcomes, we com- pared the two formulations of vaccines among members of the Kaiser Permanente Northern California (KPNC) health care system who were between 18 and 64 years of age during the two influenza seasons of 2018-2019 and 2019-2020.",
      "relevance_explanation": "This quote confirms that the study compared the effectiveness of Flublok (recombinant vaccine) with standard dose vaccines, directly supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "This was a cluster randomized observational study that was designed to include all KPNC members between the ages of 18 and 64 years who had received a licensed recombinant or standard dose vaccine as part of routine clinical care during the three influenza seasons from 2018 to 2021.",
      "relevance_explanation": "This quote further supports the claim by stating that the study included participants who received either the recombinant (Flublok) or standard dose vaccine, indicating a direct comparison.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}